Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Buy
65
BDX Quote, Financials, Valuation and Earnings
Last price:
$175.79
Seasonality move
:
0.92%
Day range:
$175.72 - $180.23
52-week range:
$127.54 - $184.94
Dividend yield:
1.86%
P/E ratio:
28.73x
P/S ratio:
2.30x
P/B ratio:
1.98x
Volume:
3.2M
Avg. volume:
3M
1-year change:
-0.53%
Market cap:
$50B
Revenue:
$21.8B
EPS (TTM):
$6.12
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
$5.1B | $2.80 | -10.87% | 159.59% | $195.38 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 54.88% | $133.39 |
|
BAX
Baxter International, Inc.
|
$2.8B | $0.54 | -0.45% | 29.73% | $21.77 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.32% | 75.65% | $106.78 |
|
IART
Integra LifeSciences Holdings Corp.
|
$429.6M | $0.80 | 2.48% | 217.65% | $15.50 |
|
WST
West Pharmaceutical Services, Inc.
|
$794.8M | $1.83 | 11.64% | 36.19% | $329.64 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
$175.89 | $195.38 | $50B | 28.73x | $0.83 | 1.86% | 2.30x |
|
ABT
Abbott Laboratories
|
$112.68 | $133.39 | $195.9B | 30.43x | $0.63 | 2.13% | 4.44x |
|
BAX
Baxter International, Inc.
|
$19.79 | $21.77 | $10.2B | 167.20x | $0.01 | 2.63% | 0.90x |
|
BSX
Boston Scientific Corp.
|
$74.73 | $106.78 | $110.8B | 38.54x | $0.00 | 0% | 5.56x |
|
IART
Integra LifeSciences Holdings Corp.
|
$11.32 | $15.50 | $881.7M | 70.14x | $0.00 | 0% | 0.53x |
|
WST
West Pharmaceutical Services, Inc.
|
$250.49 | $329.64 | $18B | 36.86x | $0.22 | 0.34% | 5.92x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
43.59% | -0.585 | 44.99% | 0.40x |
|
ABT
Abbott Laboratories
|
20.25% | 0.141 | -- | 1.12x |
|
BAX
Baxter International, Inc.
|
61.48% | -0.563 | 99.84% | 1.33x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.200 | -- | 0.81x |
|
IART
Integra LifeSciences Holdings Corp.
|
65.91% | -0.228 | 179.84% | 1.47x |
|
WST
West Pharmaceutical Services, Inc.
|
9.18% | 1.536 | 1.62% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
$2.4B | $700M | 3.93% | 6.94% | 13.33% | $549M |
|
ABT
Abbott Laboratories
|
$6.5B | $2.4B | 10.2% | 29.06% | 20.59% | $2.3B |
|
BAX
Baxter International, Inc.
|
$870M | $117M | -5.13% | -12.97% | 3.93% | $444M |
|
BSX
Boston Scientific Corp.
|
$3.7B | $1B | 8.4% | 12.46% | 19.69% | $1.2B |
|
IART
Integra LifeSciences Holdings Corp.
|
$226.1M | $25.9M | -14.85% | -37.15% | 6.43% | $25.8M |
|
WST
West Pharmaceutical Services, Inc.
|
$303.9M | $157.1M | 15.36% | 17% | 19.52% | $175M |
Becton, Dickinson & Co. vs. Competitors
-
Which has Higher Returns BDX or ABT?
Abbott Laboratories has a net margin of 7.27% compared to Becton, Dickinson & Co.'s net margin of 15.5%. Becton, Dickinson & Co.'s return on equity of 6.94% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.45.91% $1.34 $44.8B ABTAbbott Laboratories57.09% $1.02 $64.2B -
What do Analysts Say About BDX or ABT?
Becton, Dickinson & Co. has a consensus price target of $195.38, signalling upside risk potential of 11.08%. On the other hand Abbott Laboratories has an analysts' consensus of $133.39 which suggests that it could grow by 18.38%. Given that Abbott Laboratories has higher upside potential than Becton, Dickinson & Co., analysts believe Abbott Laboratories is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.4 9 0 ABTAbbott Laboratories15 7 0 -
Is BDX or ABT More Risky?
Becton, Dickinson & Co. has a beta of 0.248, which suggesting that the stock is 75.233% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.138%.
-
Which is a Better Dividend Stock BDX or ABT?
Becton, Dickinson & Co. has a quarterly dividend of $0.83 per share corresponding to a yield of 1.86%. Abbott Laboratories offers a yield of 2.13% to investors and pays a quarterly dividend of $0.63 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Abbott Laboratories pays out 64.34% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or ABT?
Becton, Dickinson & Co. quarterly revenues are $5.3B, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Becton, Dickinson & Co.'s net income of $382M is lower than Abbott Laboratories's net income of $1.8B. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 28.73x while Abbott Laboratories's PE ratio is 30.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.30x versus 4.44x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.30x 28.73x $5.3B $382M ABTAbbott Laboratories4.44x 30.43x $11.5B $1.8B
-
Which has Higher Returns BDX or BAX?
Baxter International, Inc. has a net margin of 7.27% compared to Becton, Dickinson & Co.'s net margin of -34.8%. Becton, Dickinson & Co.'s return on equity of 6.94% beat Baxter International, Inc.'s return on equity of -12.97%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.45.91% $1.34 $44.8B BAXBaxter International, Inc.29.25% -$2.16 $15.9B -
What do Analysts Say About BDX or BAX?
Becton, Dickinson & Co. has a consensus price target of $195.38, signalling upside risk potential of 11.08%. On the other hand Baxter International, Inc. has an analysts' consensus of $21.77 which suggests that it could grow by 9.99%. Given that Becton, Dickinson & Co. has higher upside potential than Baxter International, Inc., analysts believe Becton, Dickinson & Co. is more attractive than Baxter International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.4 9 0 BAXBaxter International, Inc.2 13 1 -
Is BDX or BAX More Risky?
Becton, Dickinson & Co. has a beta of 0.248, which suggesting that the stock is 75.233% less volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.747%.
-
Which is a Better Dividend Stock BDX or BAX?
Becton, Dickinson & Co. has a quarterly dividend of $0.83 per share corresponding to a yield of 1.86%. Baxter International, Inc. offers a yield of 2.63% to investors and pays a quarterly dividend of $0.01 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Baxter International, Inc.'s is not.
-
Which has Better Financial Ratios BDX or BAX?
Becton, Dickinson & Co. quarterly revenues are $5.3B, which are larger than Baxter International, Inc. quarterly revenues of $3B. Becton, Dickinson & Co.'s net income of $382M is higher than Baxter International, Inc.'s net income of -$1B. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 28.73x while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.30x versus 0.90x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.30x 28.73x $5.3B $382M BAXBaxter International, Inc.0.90x 167.20x $3B -$1B
-
Which has Higher Returns BDX or BSX?
Boston Scientific Corp. has a net margin of 7.27% compared to Becton, Dickinson & Co.'s net margin of 12.68%. Becton, Dickinson & Co.'s return on equity of 6.94% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.45.91% $1.34 $44.8B BSXBoston Scientific Corp.69.58% $0.45 $35.7B -
What do Analysts Say About BDX or BSX?
Becton, Dickinson & Co. has a consensus price target of $195.38, signalling upside risk potential of 11.08%. On the other hand Boston Scientific Corp. has an analysts' consensus of $106.78 which suggests that it could grow by 42.89%. Given that Boston Scientific Corp. has higher upside potential than Becton, Dickinson & Co., analysts believe Boston Scientific Corp. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.4 9 0 BSXBoston Scientific Corp.26 0 0 -
Is BDX or BSX More Risky?
Becton, Dickinson & Co. has a beta of 0.248, which suggesting that the stock is 75.233% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.
-
Which is a Better Dividend Stock BDX or BSX?
Becton, Dickinson & Co. has a quarterly dividend of $0.83 per share corresponding to a yield of 1.86%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or BSX?
Becton, Dickinson & Co. quarterly revenues are $5.3B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Becton, Dickinson & Co.'s net income of $382M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 28.73x while Boston Scientific Corp.'s PE ratio is 38.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.30x versus 5.56x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.30x 28.73x $5.3B $382M BSXBoston Scientific Corp.5.56x 38.54x $5.3B $670M
-
Which has Higher Returns BDX or IART?
Integra LifeSciences Holdings Corp. has a net margin of 7.27% compared to Becton, Dickinson & Co.'s net margin of -1.34%. Becton, Dickinson & Co.'s return on equity of 6.94% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.45.91% $1.34 $44.8B IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B -
What do Analysts Say About BDX or IART?
Becton, Dickinson & Co. has a consensus price target of $195.38, signalling upside risk potential of 11.08%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 36.93%. Given that Integra LifeSciences Holdings Corp. has higher upside potential than Becton, Dickinson & Co., analysts believe Integra LifeSciences Holdings Corp. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.4 9 0 IARTIntegra LifeSciences Holdings Corp.2 4 2 -
Is BDX or IART More Risky?
Becton, Dickinson & Co. has a beta of 0.248, which suggesting that the stock is 75.233% less volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.036, suggesting its more volatile than the S&P 500 by 3.641%.
-
Which is a Better Dividend Stock BDX or IART?
Becton, Dickinson & Co. has a quarterly dividend of $0.83 per share corresponding to a yield of 1.86%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or IART?
Becton, Dickinson & Co. quarterly revenues are $5.3B, which are larger than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Becton, Dickinson & Co.'s net income of $382M is higher than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 28.73x while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.30x versus 0.53x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.30x 28.73x $5.3B $382M IARTIntegra LifeSciences Holdings Corp.0.53x 70.14x $402.1M -$5.4M
-
Which has Higher Returns BDX or WST?
West Pharmaceutical Services, Inc. has a net margin of 7.27% compared to Becton, Dickinson & Co.'s net margin of 16.41%. Becton, Dickinson & Co.'s return on equity of 6.94% beat West Pharmaceutical Services, Inc.'s return on equity of 17%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.45.91% $1.34 $44.8B WSTWest Pharmaceutical Services, Inc.37.75% $1.82 $3.5B -
What do Analysts Say About BDX or WST?
Becton, Dickinson & Co. has a consensus price target of $195.38, signalling upside risk potential of 11.08%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $329.64 which suggests that it could grow by 31.6%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe West Pharmaceutical Services, Inc. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.4 9 0 WSTWest Pharmaceutical Services, Inc.11 3 0 -
Is BDX or WST More Risky?
Becton, Dickinson & Co. has a beta of 0.248, which suggesting that the stock is 75.233% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.181, suggesting its more volatile than the S&P 500 by 18.063%.
-
Which is a Better Dividend Stock BDX or WST?
Becton, Dickinson & Co. has a quarterly dividend of $0.83 per share corresponding to a yield of 1.86%. West Pharmaceutical Services, Inc. offers a yield of 0.34% to investors and pays a quarterly dividend of $0.22 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.67% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or WST?
Becton, Dickinson & Co. quarterly revenues are $5.3B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $805M. Becton, Dickinson & Co.'s net income of $382M is higher than West Pharmaceutical Services, Inc.'s net income of $132.1M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 28.73x while West Pharmaceutical Services, Inc.'s PE ratio is 36.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.30x versus 5.92x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.30x 28.73x $5.3B $382M WSTWest Pharmaceutical Services, Inc.5.92x 36.86x $805M $132.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
